Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - methotrexate, quantity: 500 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - antineoplastic chemotherapy:,methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of drug induced remissions.,high dose therapy:,in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic sarcoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy.,psoriasis chemotherapy (see warnings box and section 4.4 special warnings and precautions for use):,methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after diagnosis has been definitely established , as by biopsy and/or after dermatological consultation.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cytarabine, quantity: 100 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - cytarabine may be used alone or in combination with other chemotherapeutic agents. it is indicated for induction of remission of leukaemia, particularly for acute myeloid leukaemia, in adults and children. cytarabine has been used for remission induction in acute lymphocytic leukaemia, chronic myeloid leukaemia and erythroleukaemia; and in the treatment and maintenance therapy of meningeal leukaemia and other meningeal neoplasms.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cytarabine, quantity: 100 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - cytarabine may be used alone or in combination with other chemotherapeutic agents. it is indicated for induction of remission of leukaemia, particularly for acute myeloid leukaemia, in adults and children. cytarabine has been used for remission induction in acute lymphocytic leukaemia, chronic myeloid leukaemia and erythroleukaemia; and in the treatment and maintenance therapy of meningeal leukaemia and other meningeal neoplasms.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cytarabine -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cytarabine -

Malta - anglès - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - vincristine sulfate - solution for infusion or injection - vincristine sulfate 1 mg/ml - antineoplastic agents

Canadà - anglès - Health Canada

accord healthcare inc - methotrexate (methotrexate disodium) - tablet - 2.5mg - methotrexate (methotrexate disodium) 2.5mg - antineoplastic agents

Canadà - anglès - Health Canada

auro pharma inc - methotrexate (methotrexate disodium) - tablet - 2.5mg - methotrexate (methotrexate disodium) 2.5mg

Canadà - anglès - Health Canada

mantra pharma inc - methotrexate (methotrexate disodium) - tablet - 2.5mg - methotrexate (methotrexate disodium) 2.5mg

Israel - anglès - Ministry of Health

abic marketing ltd, israel - methotrexate - solution for injection - methotrexate 25 mg/ml - methotrexate - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. abitrexate is also indicated in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, abitrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. abitrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, abitrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: abitrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.